soft tissue sarcomas

close-up of money
Biotech

Shasqi snatches $50M for chemotherapy-boosting treatments

Shasqi has collected $50 million in a series B financing to fuel the path through the clinic. 
Emmy Lucas Nov 11, 2021 6:30am
Laboratory

ASCO: Adaptimmune’s cell therapy shrinks 39% of rare sarcomas

May 19, 2021 5:00pm
FDA Building

Epizyme's sarcoma drug sails through FDA panel

Dec 18, 2019 6:23pm
FDA Building 2

FDA raises doubts about benefits of Epizyme's cancer drug

Dec 17, 2019 8:10am
ASCO 2019 sign outside McCormick Place

With FDA review nearing, Epizyme shares updated sarcoma data

Jun 3, 2019 9:15am
greenlight

ESMO18: Tazemetostat update sets Epizyme up for first FDA filing

Oct 22, 2018 8:00am